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Simple Summary: Laryngeal paralysis is secondary to a loss of normal function of the larynx. Older
dogs are particularly affected, with normal breathing becoming difficult. A successful diagnosis
typically relies on the visualisation of either, complete, or partially absent, laryngeal movements.
The use of anaesthesia drugs to provide sedation and stress relief is most commonly necessary
during the diagnosis of laryngeal paralysis. While, the excessive administration of anaesthesia drugs
may result in absent movements, the ideal anaesthesia regime remains unknown, and the use of
sedation is questionable, given the potential for absent laryngeal movements, even in healthy dogs.
In this systematic review, we found a potential benefit from using sedation during the evaluation
of laryngeal function when compared to injectable anaesthetics only. The respiratory stimulant
doxapram was effective in differentiating normal dogs from dogs with laryngeal paralysis but has
associated safety hazards.
Abstract: Anaesthetic drugs are commonly used during the evaluation of laryngeal function in dogs.
The aim of this review was to systematically analyse the literature describing the effects of anaesthetic
drugs and doxapram on laryngeal motion in dogs and to determine which drug regime provides
the best conditions for laryngeal examination. PubMed, Google Scholar, and EMBASE databases
were used for the literature search up to November 2019. Relevant search terms included laryngeal
motion, anaesthetic drugs and dogs. Studies were scored based on their level of evidence (LoE),
according to the Oxford Centre for Evidence-based Medicine, and the quality was assessed using the
risk-of-bias tool and SIGN-checklist. In healthy dogs, premedication before laryngeal examination
provided better examination conditions and maintained overall adequate laryngeal motion in 83% of
the studies. No difference in laryngeal motion between induction drugs was found in 73% of the
studies but the effects in dogs with laryngeal paralysis remain largely unknown. Doxapram increased
laryngeal motion in healthy dogs without serious side effects, but intubation was necessary for some
dogs with laryngeal paralysis. Methodological characteristics varied considerably between studies,
including the technique and timing of evaluation, number of assessors, study design, drug dose,
combinations, route and speed of administration.
Keywords: laryngeal motion; anaesthesia; dogs; doxapram
1. Introduction
The use of anaesthetic drugs to provide a light plane of anaesthesia is usually inevitable in dogs,
to allow visualisation of arytenoid motion during the diagnosis of laryngeal paralysis. In healthy dogs,
bilateral arytenoid abduction is normally observed during inspiration. However, if the anaesthetic
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depth is excessive, arytenoid function can be lost. Most anaesthetics inhibit arytenoid motion in a
dose-depended manner, possibly leading to a false diagnosis of laryngeal paralysis [1].
Laryngeal paralysis has a high prevalence in canines, in which both the hereditary or acquired
form exist [2]. The most common acquired form is idiopathic, secondary to a progressive degenerative
neuropathy, and while this can occur in all breeds, it is typically found in older-aged dogs [3]. The
diagnosis of laryngeal paralysis is typically made either via direct observation or video laryngoscopy.
However, no standardisation for this procedure has been described [4,5]. The ideal anaesthetic protocol
for examination should provide adequate sedation and jaw relaxation, without decreasing arytenoid
motion and causing minimal respiratory depression. Providing an ideal anaesthetic plane can be
challenging, as slow titration of anaesthetic drugs can result in excitement, whereas fast titration might
ensure absent reflexes. It might also result in the suppression of arytenoid motion and subsequent
intubation of the trachea. The majority of studies in veterinary medicine use different anaesthetic
protocols during the diagnosis of laryngeal paralysis and different evaluation methods. While some
authors avoid the use of sedatives [6], others recommend their use to provide better conditions for
examination, in adjunct to doxapram to stimulate laryngeal motion [7]. To date, there is no consensus
over either, sedative or anaesthetic management, or for the use of respiratory stimulants during the
evaluation of the laryngeal function in dogs.
Therefore, the aims of this review were: (i) To determine the extent to which premedication
drugs are used during the diagnosis of laryngeal paralysis in dogs and to determine their effects
on laryngeal motion; (ii) to determine the effects of induction agents on laryngeal motion and the
diagnosis of laryngeal paralysis; (iii) to establish whether any drug regime provides the best conditions
and improved safety for the dogs during laryngeal examination; and (iv) to establish whether the use
of doxapram is indicated and safe for the diagnosis of laryngeal paralysis.
2. Materials and Methods
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines
and checklist were consulted and adhered to during the review design and development phase [8].
Three internet databases were searched to identify the studies for review, including PubMed, Google
Scholar, and the EMBASE database. The full search strategy is shown in Figure 1. Papers available
through the University of Zurich were also used. Keywords entered were “laryngeal paralysis”,
“laryngeal function”, “laryngeal motion”, “anaesthetic drugs”, “anaesthesiological procedure”, “dogs”
and “doxapram”. Articles were excluded if they met any of the following exclusion criteria: (i) Did not
describe the anaesthetic regime; (ii) belonged to a different species other than dogs; (iii) failed to report
relevant anaesthetic drug information such as resulting effect, dosage or route of administration. In the
first stage, the effects of premedication drugs on the laryngeal motion in dogs were evaluated. In the
second stage, induction drugs were assessed. Only primary research articles in English, describing the
use of anaesthetic drugs (including the dose and route of administration) during the evaluation of
laryngeal function in dogs were selected (Table 1). The quality and method of laryngeal examination
were compared between trials. In the third stage, the use of doxapram for the diagnosis of laryngeal
paralysis was evaluated. Articles were categorised on the basis of premedication, induction and
stimulating agent used (Tables 2–4).
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Table 1. Results and study features of standardised methodological assessment of the 12 included studies evaluating the effects of anaesthetic drugs on the laryngeal
motion in dogs.
Reference Journal Study design Number ofDogs
Health
Status Group Size
Prospective
Power
Calculation
Evaluation Method Assessment of LaryngealFunction
Laryngeal Function
Assessed during
Inspiratory Cycle
Statistical Analysis
Brown et al.
(2019) [10] Veterinary surgery
Prospective, controlled
randomised blinded
40 shelter
dogs Healthy 10/10/10/10 Yes
Normalised glottal gap
area (NGAA)
Direct visualisation and video
from videolaryngoscopy Yes ANOVA
DeGroot et
al. (2019) [7]
Veterinary surgery
Prospective
randomised crossover
8 research
dogs
Healthy 8/8/8/8 No
Video laryngoscopy,
normalised glottal gap
area (NGAA)
Still images from
videolaryngoscopy Yes ANOVA
blinded
Labuscagne
et al. (2019)
[11]
Veterinary anaesthesia
and analgesia
Prospective
randomized crossover
8 research
dogs
Healthy 8/8/8/8/8/8 No Visual subjective Subjective laryngeal exposure
score
Yes
Friedman rank sum
test/Wilcoxon rank sum
test/ANOVA/blinded
Norgate et al.
(2018) [12]
Veterinary anaesthesia
and analgesia
Prospective
randomized, blinded
48
client-owned
dogs
Healthy
brachy-cephalic 24/24 No
Video laryngoscopy,
visual subjective
Subjective laryngeal exposure
score and video from
videolaryngoscopy
Yes
Shapiro-Wilk test/
Chi square and Fisher’s
exact tests
Radkey et al.
(2018) [13]
Veterinary anaesthesia
and analgesia
Prospective
randomized controlled
crossover, blinded
10 research
dogs Healthy 10/10/10/10 Yes
Normalised rima
glottides surface area
(RGSA)
Video and still images from
videolaryngoscopy Yes
Shapiro-Wilk
test/ANOVA/Kruskal-Wallis
Ambros et al.
(2018) [14]
Canadian veterinary
journal
Prospective, crossover
randomised blinded
8
client-owned
dogs
Healthy 2008/8/8 Yes Normalised glottal gaparea (NGAA)
Direct visualisation and still
images from
videolaryngoscopy
Yes Kruskal-Wallis
Smalle et al.
(2017) [15]
Veterinary anaesthesia
and analgesia
Prospective
randomized crossover,
blinded
6 research
dogs Healthy 2006/6/6 No Visual subjective
Subjective laryngeal exposure
score Yes
Friedman/Mann-Whitney
U tests, Spearman
McKeirnan
et al. (2014)
[16]
Journal of the American
Animal Hospital
Association
Prospective
randomized, blinded
48 shelter
dogs Healthy 24/24 No Visual subjective
Subjective laryngeal exposure
score Yes
T test and Fischer exact
test
Jackson et al.
(2004) [6]
Veterinary surgery
Prospective
randomized crossover 6 dogs Healthy 6/6/6/6/6/6/6 No
Normalised glottal gap
area (NGAA)
Video and still images from
videolaryngoscopy Yes ANOVA/Students t test
blinded
Tobias et al.
(2004) [17]
Veterinary anaesthesia
and analgesia
Prospective
experimental and
clinical
12 dogs Healthy/laryngealparalysis 6-6 No
Normalised glottal gap
area (NGAA)
Video and still images from
videolaryngoscopy Yes
Wilcoxon rank sum
test/t-test/Mann-Whitney
test
Gross et al.
(2002) [18]
Journal of the American
Animal Hospital
Association
Prospective
randomized crossover 8 dogs Healthy 2008/8/8 No Visual subjective Direct visualisation Yes ANOVA
blinded
Miller et al.
(2002) [19]
Journal of Veterinary
Internal Medicine
Prospective 30 research
dogs
Healthy 30 No
Normalised rima
glottides surface area
(RGSA)
Video and still images from
videolaryngoscopy Yes
Kolmogorov-Smirnov
/ANOVA
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Table 2. Characteristics and study design features from 8 studies evaluating the effects of premedication on laryngeal motion in dogs.
Premedication Agent Dose Induction Agent Timing beforeInduction
Improved
Examination
Conditions
Results StatisticalSignificance Reference
Dexmedetomidine
vs. Butorphanol +
dexmedetomidine
vs. Hydromorphone +
dexmedetomidine
15 µg kg−1 IV dexmedetomidine
0.3 mg kg−1 IV butorphanol + 7 µg kg−1 IV
dexmedetomidine
0.1 mg kg−1 IV hydromorphone + 5 µg kg−1
IV dexmedetomidine
No To effect Yes
Normal laryngeal
motion with all
protocols
No DeGroot et al.(2019) [7]
Acepromazine +
methadone
0.01 mg kg−1 IM acepromazine + 0.2 mg kg−1
IM methadone
Yes–alfaxalone/propofol 30 min prior toinduction N/D
>75% maintained
laryngeal motion N/D
Norgate et al.
(2018) [12]
Acepromazine +
butorphanol
vs. saline (control)
0.03 mg kg−1 IV acepromazine + 0.2 mg kg−1
IV butorphanol
vs. saline (non-premedicated control group)
Yes–alfaxalone/propofol 5 min prior toinduction Yes
No arytenoid
motion in 50% of
dogs
Yes Radkey et al.(2018) [13]
Butorphanol 0.5 mg kg−1 IV butorphanol Yes–propofol/ketamine 20 min prior to
induction
N/D N/D N/A McKeirnan et al.
(2014) [16]good conditions
Butorphanol 0.5 mg kg−1 IV butorphanol Yes–thiopental/propofol 5 min prior toinduction N/D
Laryngeal motion
observable N/A
Gross et al. (2002)
[18]
Acepromazine +
butorphanol
0.2 mg kg−1 IM acepromazine + 0.4 mg kg−1
IV butorphanol
Yes–mask isoflurane 20 min prior toinduction N/D
Arytenoid motion
maintained Yes
Jackson et al.
(2004) [6]
Acepromazine 0.05 mg kg−1 IM acepromazine Yes–thiopental 20 min prior toinduction N/D
Arytenoid motion
less than with
thiopental alone
Yes Jackson et al.(2004) [6]
Acepromazine +
oxymorphone
0.05 mg kg−1 IM acepromazine + 0.05 mg kg−1
IV oxymorphone
No 20 min prior toinduction N/D N/D N/A
Jackson et al.
(2004) [6]
Acepromazine +
butorphanol
0.022–0.2 mg kg−1 IM acepromazine + 0.44 mg
kg−1 IM butorphanol Yes–mask isoflurane
20 min prior to
induction N/D
Laryngeal motion
present in all
healthy dogs but
no motion in dogs
with laryngeal
paralysis
N/D Tobias et al. (2004)[17]
Acepromazine +
butorphanol
0.05 mg kg−1 SQ acepromazine + 0.22 mg kg−1
IV butorphanol
Yes–propofol 20 min/5 min priorto induction N/D N/D N/A
Miller et al. (2002)
[19]
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Table 3. Results and study features design from 12 studies evaluating the laryngeal function after the administration of induction agents.
Induction Agent Dose Sedation Titration ofInduction
Examination
Conditions/Exposure Results
Statistical
Significance Reference
Propofol
vs. methohexital
vs. saline
6.8 mg kg−1 IV propofol
7.4 mg kg−1 IV methohexital
Control IV (saline control group)
No To effect No differences No differences in laryngeal motionamong groups No Brown et al. (2019) [10]
Alfaxalone + doxapram
vs. propofol + doxapram
1.5 mg kg−1 IV alfaxalone
3.0 mg kg−1 IV propofol
2.5 mg kg−1 IV doxapram
No To effect No differences Alfaxalone-doxapram significantlyless arytenoid motions Yes
Labuscagne et al. (2019)
[11]
Propofol
vs. dexmedetomidine
6.5 mg kg−1 IV propofol
15 µg kg−1 IV dexmedetomidine No To effect
Good except one
dog in propofol
group
Laryngeal function observed in all
except propofol Yes DeGroot et al. (2019) [7]
Alfaxalone
vs. propofol + diazepamvs.
thiopental
2.6 mg kg−1 IV alfaxalone
3.8 mg kg−1 IV propofol + 0.4 mg kg−1 IV diazepam
14.2 mg kg−1 IV thiopental
No To effect N/D No differences in laryngeal motionamong groups No Ambros et al. (2018) [14]
Isoflurane 3–5% in oxygen (2 L/min) Yes To effect N/D
Active laryngeal motion detected in
all healthy dogs but in none of the
dogs with suspected laryngeal
paralysis
N/A Tobias et al. (2004) [17]
Thiopental
vs. propofol
vs. ketamine + diazepam
vs. acepromazine +
thiopental
vs. acepromazine + propofol
vs. isoflurane
14 mg kg−1 IV thiopental
5.6 mg kg−1 IV propofol
8.5 mg kg−1 IV ketamine + 0.4 mg kg−1 IV diazepam
0.05 mg kg−1 IM acepromazine + 9.8 mg kg−1 IV
thiopental 0.05 mg kg−1 IM acepromazine + 3.7 mg
kg−1 IV propofol
N/D
Yes To effect N/D
After induction: no differences in
laryngeal motion among groups.
Prior to recovery, thiopental superior
motion
No/Yes Jackson et al. (2004) [6]
Propofol
vs. thiopental
vs. ketamine + diazepam
3.6 mg kg−1 IV propofol
10.4 mg kg−1 IV thiopental5.6 mg kg−1 IV ketamine +
0.3 mg kg−1 IV diazepam
Yes To effect
Exposure lower in
ketamine/
diazepam
Laryngeal function observed with all
protocols. No Gross et al. (2002) [18]
Propofol 4.0 mg kg−1 IV propofol Yes No N/D N/D N/A Miller et al. (2002) [19]
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Table 4. The effects of doxapram on the laryngeal motion in healthy dogs and dogs with laryngeal paralysis.
Respiratory
Stimulant
Dose (bolus)
/(Titration) Health Status Pre-medication Induction of Anaesthesia Adverse Effects Results
Passive or
Paradoxical
Arytenoid
Motion
Statistical
Significance Reference
Doxapram
vs. control
2.2 mg kg−1
IV/saline
(control)
Healthy No Propofol/methohexital Exaggerated laryngealmovements
Doxapram improved
breathing scores but not
laryngeal function
No No Brown et al.(2019) [10]
Doxapram 1.0 mg kg
−1
IV
Healthy Dexmedetomidine/Butorphanol/Hydromorphone Propofol/ dex-medetomidine No
Doxapram improved
laryngeal function in
dogs receiving
dexmedetomidine. No
improvements in the
other drug protocols
Yes, prior to
doxapram in
propofol
group
Yes DeGroot et al.(2019) [7]
Doxapram
vs.
Mechanical
stimulation
2.5 mg kg−1
IV
Healthy No Alfaxalone/propofol/thiopental No
Doxapram more effective
in stimulating laryngeal
motion. Examination
time longest with
alfaxalone, despite
doxapram
No Yes Labuscagne etal. (2019) [11]
Doxapram 0.25 mg kg
−1
IV
Healthy Acepromazine + Butorphanol/control group Alfaxalone/propofol
Increased respiratory
drive
After doxapram,
laryngeal motion present
in all healthy dogs with
previously lacking
laryngeal motion. RGSA
was significantly less in
ALF before doxapram
compared with all other
treatments and after
doxapram 50% of dogs in
alfaxalone no motion
Yes, in dogs
with
previously
good motion
Yes Radkey et al.(2018) [13]
Doxapram 1 mg kg−1 IV Healthy Butorphanol Propofol/ketamine/propofol None
Doxapram improved
respiratory scores and
significantly increased
the ability to determine
normal laryngeal
function
No Yes McKeirnan etal. (2014) [16]
Doxapram 2–5 mg kg
−1
IV
Healthy Acepromazine
/Butorphanol Multiple N/D N/D N/D N/A
Jackson et al.
(2004) [6]
Doxapram 1.1 mg kg
−1
IV
Healthy and
with laryngeal
paralysis
Butorphanol/Acepromazine Isoflurane by mask Intubation necessary
Healthy dogs
differentiated from dogs
with laryngeal paralysis
with doxapram
Yes, in dogs
with laryngeal
paralysis
Yes Tobias et al(2004) [17]
Doxapram 2.2 mg kg−1 Healthy Acepromazine + Butorphanol Propofol Excitement/awakening
Doxapram increased
laryngeal motion in
healthy premedicated
dogs
No Yes Miller et al.(2002) [19]
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Assessment of Study Quality and Level of Evidence
Manuscripts were scored based on their level of evidence (LoE) following the 2011 Oxford Centre
for Evidence-based Medicine approach, which includes high quality levels (I-LoE) with evidence
obtained from a systematic review and lower quality (II-LoE) with evidence obtained from properly
designed, randomised controlled trials or non-randomised trials (III-LoE) [20]. The methodological
quality of the studies was assessed according to the modified SIGN Methodology Checklist 2 of
randomised controlled trials (RCTs), in which a bias rating of low (++) moderate (+), or high (-) is
provided, based on ten questions [21]. The modified checklist consisted of 10 criteria, with each
criterion receiving a score of either one or two points. When all criteria were adequately described
and the sum of the scores resulted in 10–11 points, a double plus was assigned. A plus sign was
given to studies scoring over seven points and a minus for studies scoring under seven points. Data
extraction and risk-of-bias assessment were performed by two individual evaluators, with a third
involved in cases of disagreement. Table 5 shows the modified methodology checklist, including the
scoring system, and LoE.
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Table 5. Quality assessment of the 12 studies included using the modified SIGN Criteria for RCTs and their assigned levels of evidence (LoE).
Quality Criterion. Score
Labuscagne
et al.
(2019)
[11]
Brown
et al.
(2019)
[10]
DeGroot
et al.
(2019)
[7]
Norgate
et al.
(2018)
[12]
Radkey
et al.
(2018)
[13]
Smalle
et al.
(2017)
[15]
Ambros
et al.
(2018)
[14]
McKeirnan
et al.
(2014)
[16]
Tobias
et al.
(2004)
[17]
Jackson
et al.
(2004)
[6]
Gross et
al.
(2002)
[18]
Miller
et al.
(2002)
[19]
Clear question addressed by study Yes 1 1 1 1 1 1 1 1 1 1 1 1 1
No 0 / / / / / / / / / / / /
Acceptable randomization method
Yes 1 1 1 / 1 1 1 / 1 / 1 / /
No 0 / / / / / / / / / / / /
N/R 0 / / 0 / / / 0 / 0 / 0 0
Adequate concealment method
Yes 1 1 1 1 / / 1 / 1 / / / /
No 0 / / / / / / / / 0 / / /
N/R 0 / / / 0 0 / 0 / / 0 0 0
Blinding of assessors
Yes 1 1 1 1 1 1 1 1 1 / 1 1 /
No 0 / / / / / / / / / / / /
N/R 0 / / / / / / / / 0 / / 0
Assessment videolaryngoscopy and direct
observation
Yes 2 / 2 / 2 / / 2 / / / / /
No 0 / / / / / / / / / / / /
One
only 1 1 / 1 / 1 1 / 1 1 1 1 1
Agreement between assessors
Yes 1 / / / 1 / / / / / / / /
No 0 / 0 / / / / / 0 / / / /
N/R or
N/A 0 0 / 0 / 0 0 0 / 0 0 0 0
Groups similar at baseline Yes 1 1 1 1 1 1 1 1 1 1 1 1 1
No 0 / / / / / / / / / / / /
Only difference between groups is the
anaesthetic drug or doxapram
Yes 1 1 1 1 1 1 1 1 1 1 1 1 1
No 0 / / / / / / / / / / / /
Outcomes measurements are standard, valid
and reliable
Yes 1 1 1 1 1 1 1 1 1 1 1 1 1
No 0 / / / / / / / / / / / /
Intention-to-treat (ITT)
Yes 1 1 1 1 1 1 1 1 1 1 1 1 1
No 0 / / / / / / / / / / / /
Overall bias rating
(++)
(+) (+) (++) (+) (++) (+) (+) (+) (+) (−) (+) (+) (+)
(−)
Level of evidence (LoE) I-V II II II II II II II II III II II III
RCTS: Randomised controlled trials; N/R, not reported; N/A, not available. Level of evidence (according to Oxford Centre of Evidence-based Medicine 2011) (range 1 = highest to range 5 =
lowest). SIGN=Methodology Checklist 2 of Controlled Trials: Low risk of bias (++), medium risk of bias (+), high risk of bias (−).
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3. Results
The first literature search identified 47 potentially eligible articles, of which 27 articles were
excluded after reviewing the abstracts, as they did not meet the inclusion criteria or met the exclusion
criteria. Of the 20 studies included for full-text analysis, eight were excluded by the exclusion criteria.
Twelve prospective studies were included in the qualitative synthesis, including eight randomised
studies, two controlled, and one clinical study (Table 1). The total number of dogs involved in the
remaining 12 reviewed articles were 232, of which 54 dogs were research animals. Three studies failed
to report the source of the dogs. The sample sizes varied considerably, with a mean of 19 (range
6–48) dogs per study. Three studies reported a prospective power calculation [13,14]. Most studies
(83%) used a randomised method of drug allocation but not all described an acceptable method of
randomisation (Table 5). Some studies (66%) were designed in a crossover fashion and the evaluators
were unaware of the treatment allocation. Only one of the studies included dogs with suspected
laryngeal paralysis, in a non-blinded, non-randomised design [17]. Most studies (83%) provided a
direct comparison between anaesthetic drugs, with two studies including a control group [10,13]. A
total of 58% of studies evaluated laryngeal function objectively by measurement of the normalised
glottal gap area (NGAA) or normalised rima glottides surface area (RGSA) via video laryngoscopy. Few
studies (33%) used a subjective scoring method via direct visualisation. Methodological characteristics
of the studies are summarised in Table 1. In Table 5, the level of evidence (LoE) and the quality
assessments are shown.
3.1. Effects of Premedication Drugs and Influence on the Quality of Laryngeal Examination
Premedication was used in 66% of the studies during the evaluation of laryngeal motion. Five out
of 8 (62%) studies did not report the conditions or quality of sedation during the laryngeal examination.
In the remaining studies, good evaluation conditions were found in premedicated dogs (Table 2). In
two comparative studies, the direct effects between premedication and lack of premedication on the
quality of laryngeal examination were analysed. A significant improvement in laryngeal exposure
scores was obtained in dogs premedicated with butorphanol and acepromazine when compared to
non-premedicated dogs [7,13].
In the first stage, studies (level II) were evaluated for the use of premedication drugs during the
evaluation of laryngeal motion in dogs (Table 2). Premedication drugs were used in 8 out of 12 (66%)
studies. Of these, 25% used one sedative only, whereas 75% reported using at least two sedatives. A
total of six premedication drugs were evaluated, including four opioids (butorphanol, methadone,
hydromorphone and oxymorphone), one alpha-two adrenergic agonist (dexmedetomidine) and one
phenothiazine derivate (acepromazine). The effects of premedication drugs were evaluated after the
induction of anaesthesia in all studies except for one [7]. In this study, the effects of premedication
were studied independently of induction drugs, concluding that laryngeal function was present in
all sedated dogs, but was absent when propofol only was administered. By contrast, one level II
study providing a direct comparison between the effects of premedication and lack of premedication
concluded that, while premedication improved the quality of the laryngeal examination, 50% of
premedicated animals had absent laryngeal function [13]. Two studies using premedication failed to
analyse the effects of premedication on laryngeal function [16,19]. The overall laryngeal function of
the studies analysing the effects of premedication concluded that premedication maintained (75% or
higher) adequate laryngeal motion in 5 out of 6 (83%) of healthy dogs and provided better conditions
for the laryngeal examination.
3.1.1. Dexmedetomidine
The effects of dexmedetomidine were evaluated in one study, which was the only titrating
premedication to effect (Table 2). In this study, Degroot et al. determined the ability to evaluate
laryngeal function under sedation with dexmedetomidine alone, or in combination with butorphanol,
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hydromorphone or compared to propofol alone [7]. Drug dosages can be found in Table 2. Laryngeal
function was observed in all dogs receiving dexmedetomidine, with, or without, opioids but was
absent in two dogs in the propofol group. It was concluded, that dexmedetomidine sedation does
not inhibit normal laryngeal motion and provided good conditions for the laryngeal examination,
even when combined with opioids. One dog vomited after dexmedetomidine, but no other side
effects were reported. No dog required intubation at the maximum dose of 15 µg kg−1 intravenous
(IV). Interestingly, laryngeal motion after the administration of doxapram was greater for dogs
receiving dexmedetomidine alone, suggesting that dexmedetomidine had the least depressive effect on
laryngeal motion.
3.1.2. Butorphanol
The effects of either butorphanol, methadone or hydromorphone on laryngeal function were
evaluated in all studies involving premedication (Table 2). Dosages for IV or intramuscular (IM)
butorphanol ranged between 0.2 to 0.5 mg kg−1. The effects of different dose range were not analysed.
Butorphanol was used in combination with another premedication drug in all studies, except for
two, in which butorphanol was the sole premedication drug [16,20]. Arytenoid motion was graded
subjectively by a blinded assessor in a crossover study and was found present in all healthy dogs
premedicated with butorphanol (0.5 mg kg−1 IV) when administered 5 min prior to induction of
anaesthesia with thiopental or propofol [18]. The effects of butorphanol were not directly analysed or
compared with a control group (placebo).
3.1.3. Acepromazine and Butorphanol
Acepromazine was combined with butorphanol for premedication in 50% of the studies. Dosages
for acepromazine ranged from 0.02 to 0.2 mg kg−1 (Table 2) and were administered either IV, IM
or subcutaneously (SQ), either 5 or 20 minutes before induction of anaesthesia. Larger doses of
acepromazine combined with butorphanol did not appear to affect laryngeal motion in healthy dogs
when anaesthesia was induced with isoflurane in a LoE III [17] and LoE II study [6]. In contrast, when
acepromazine and butorphanol were used for premedication, a lack of arytenoid motion was observed
in 50% of the dogs induced with either propofol or alfaxalone in a controlled randomised trial (level
II) [13].
3.1.4. Acepromazine and Thiopental, Propofol, Isoflurane
While in healthy dogs premedicated with acepromazine, the overall dose of the induction agent
propofol or thiopental was reduced, the laryngeal motion was absent in some dogs or significantly
decreased when compared to examinations with thiopental alone or acepromazine–butorphanol and
isoflurane combinations [6].
3.1.5. Methadone, Hydromorphone, Oxymorphone
The use of methadone, hydromorphone or oxymorphone was reported in 3 studies [6,7,17]
(Table 2), however one failed to report the degree of laryngeal motion in dogs premedicated with
oxymorphone [6]. IM premedication with methadone (combined with acepromazine) 30 min prior
to laryngeal examination resulted in a 15% loss of detectable arytenoid motion when propofol or
alfaxalone were used as induction agents [12]. In contrast, when hydromorphone was combined with
dexmedetomidine, titrated to effect, no detrimental effects were evidenced on the laryngeal motion
and sedation was excellent to perform a laryngeal examination [7].
3.2. Effects of Induction Drugs and Influence on the Quality of Laryngeal Examination
The second stage evaluated the effects of induction drugs on laryngeal function in dogs (Table 3).
A total of 33% of the studies used induction agents only. A total of five induction drugs were evaluated,
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including alfaxalone, propofol, isoflurane, methohexital and thiopental. Adjuvant drugs were used in
41% of the studies and included ketamine and diazepam. Propofol was used in each study, whereas
alfaxalone and thiopental were used in 41%, and 33% of the studies, respectively. No difference in
laryngeal motion between induction drugs [when assessed shortly after the induction of anaesthesia]
was found in 73% of the studies [6,13,14,17,18]. In the four studies in which laryngeal function was
found to be decreased, an objective scoring method had been used in three studies (LoE II) [6,7,13], and
a subjective score in one study [11]. Of all studies, only one study compared the effects of induction
drugs in both, premedicated and non-premedicated dogs, concluding that mainly non-premedicated
dogs had absent laryngeal function regardless of the induction agent [13].
When premedication was omitted, administration of alfaxalone or propofol alone did not provide
a good quality of examination when assessed by blinded observers in a controlled crossover study [13].
Also, in a crossover study, administration of propofol only resulted in insufficient sedation, gagging,
paradoxical laryngeal movements or transient paralysis [7]. In contrast, when thiopental was used
alone, better conditions for the oral laryngeal examination were achieved [15]. In dogs anaesthetised
with ketamine-diazepam, one study found poorer examination conditions [18], and another found no
differences [16]; however, in that study the agreement between assessors was poor.
3.2.1. Propofol
In six studies, no statistically significant differences were found in laryngeal function after the
administration to effect of propofol (5.1 mg kg−1 IV; range 3.6–6.8 mg kg−1 IV) when compared to
alfaxalone, methohexital, thiopental, and ketamine-diazepam mixture. Also, when propofol was
combined with diazepam, no significant differences in laryngeal motion were found when compared
to alfaxalone or thiopental [14]. Smalle et al. concluded, by direct observation, that propofol resulted
in shorter examination times and better laryngeal abduction scores when compared with alfaxalone
and thiopental [15].
In contrast, two studies showed significantly poorer laryngeal function after the induction of
anaesthesia with propofol (mean dose 6.35 mg kg−1 IV) when administered to effect in non-premedicated
dogs in studies with objective scoring methods [7,13]. While the difference was recorded in only two
dogs in one study, both dogs were false-positive for laryngeal paralysis [7]. Overall, the effects of
propofol were found to vary with individual studies. While some authors reported no respiratory
depression, others found propofol to cause apnoea [14,16,18] or absent laryngeal movements [6].
3.2.2. Alfaxalone
No significant differences were found in laryngeal function after alfaxalone (2.6 mg kg−1 IV;
range 2–3.2 mg kg−1 IV) (Table 3) administration in 3 studies, when directly compared to propofol
and thiopental in premedicated [12] and non-premedicated dogs [12,14,15]. In contrast, alfaxalone
administered at a lower dose (1.9 mg kg−1 IV; range 1.5–2.3 mg kg−1 IV), did not preserve the arytenoid
function when compared to propofol [13,16]. None of the studies combined alfaxalone with an adjuvant
drug. In the studies that found alfaxalone comparable to propofol, one used premedication and most
used a subjective scoring system (Table 1).
3.2.3. Thiopental
Thiopental was used as an induction agent in four randomised level II studies, in which a total
of 28 dogs were enrolled in a crossover design. Arytenoid motion was graded by blinded observers
(Table 1) objectively in two of the studies [6,14] and subjectively in another two [15,18]. In all studies, no
statistically significant differences were found in laryngeal function after the induction of anaesthesia
with thiopental (14.1 mg kg−1 IV; range 10.4–17.8 mg kg−1 IV) when compared to alfaxalone, propofol,
propofol-diazepam or ketamine-diazepam. However, significantly greater laryngeal motion was found
in dogs recovering from anaesthesia after previous induction with thiopental (14 mg kg−1 IV) [6].
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3.2.4. Ketamine-Diazepam
Absent arytenoid movements and lower laryngeal exposure scores due to excessive jaw tone or
laryngospasm were reported in two blinded, crossover studies using ketamine-diazepam [6,18]. Gross
et al. administered ketamine-diazepam over 1 minute to effect, whereas Jackson et al. did not report
the speed of administration [6]. When ketamine (2 mg kg−1 IV) was combined with propofol (2.4 mg
kg−1. IV), a tendency to respiratory depression, apnoea and low pulse oximetry values were found [16].
3.2.5. Methohexital
Tachycardia, seizure-like activity, vomiting and regurgitation were reported in 25% of the dogs
in a study evaluating methohexital for its effects on laryngeal motion [10]. No difference between
methohexital and propofol was detected regarding laryngeal function.
3.2.6. Isoflurane Mask Induction
Arytenoid motion assessed by an objective scoring method was preserved with isoflurane
anaesthesia [mask induction] in two prospective studies in premedicated dogs [6,17]. In one of
the studies, neither the isoflurane concentration during induction of anaesthesia nor the quality
of induction of anaesthesia were reported [6]. However, it was reported that high acepromazine
dosages (0.2 mg kg−1 IM) were necessary to allow mask induction. Laryngeal motion was maintained
adequately in a non-blinded level III study, when a face mask delivering an isoflurane concentration of
3–5%, until sufficient jaw relaxation, was achieved [17].
3.3. Agreement Between Laryngeal Function Assessors
The agreement between assessors of laryngeal function was excellent in only one study [12].
Brown et al. found disagreements in the assessment of laryngeal function, swallowing and the
incidence of laryngospasm between direct and masked observers [10]. Also, disagreement between
observers was reported by McKeirnan et al. in 58% of the cases, with some dogs being classified by
some observers as having laryngeal paralysis and healthy by others [16].
3.4. Respiratory Stimulants
3.4.1. Doxapram
Doxapram was evaluated as a respiratory stimulant in 67% of the studies and successfully increased
laryngeal motion in 75% of these studies (Table 4). In a crossover, blinded level II study, doxapram
improved laryngeal function when assessed objectively only in dogs receiving dexmedetomidine
alone and not when combined with opioids or propofol [7]. In the only controlled study, doxapram
resulted in no improved laryngeal motion in all non-premedicated dogs, however the agreement
between assessors was inconsistent [10]. Doxapram was effective in stimulating laryngeal function in
non-premedicated dogs [11]. The remaining six studies evaluated doxapram in premedicated dogs.
In one of these studies, laryngeal function was successfully observed in 40 premedicated dogs with
previously lacking arytenoid motion in a crossover design (level II) [13]. In that study, doxapram was
administered at the lowest described dose of 0.25 mg kg−1 IV, however improved laryngeal function
was not obtained in 50% of the dogs in the alfaxalone group. Overall described dosages ranged from
0.25 mg kg−1 IV to 2.5 mg kg−1 IV (Table 4). In dogs with laryngeal paralysis, the administration of
doxapram resulted in passive or paradoxical movements and intubation was necessary [17]. In healthy
dogs, side effects were limited to awakening, excitement and increased respiratory drive (Table 4).
3.4.2. Mechanical Stimulation
Mechanical stimulation of the larynx with a cotton bud was less effective in stimulating laryngeal
function than doxapram in dogs [11].
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4. Discussion
Over the past 17 years, five premedication drugs and eight induction drugs were evaluated for
their effects on the arytenoid motion in dogs. The evidence from the studies, included in this review,
demonstrated variably different effects of anaesthetic drugs on the laryngeal motion in dogs.
Overall, most studies concluded no significant differences in laryngeal motion between sedatives,
including butorphanol, acepromazine, dexmedetomidine, and between the induction drugs alfaxalone,
propofol or thiopental. However, 96% of analysed subjects in the included studies were healthy dogs.
It is possible, that the effects of anaesthesia drugs on laryngeal motion are more pronounced in dogs
with laryngeal paralysis, due to an underlying neuropathy of the recurrent laryngeal nerve, innervating
the crycoarytenoid dorsalis muscles. Therefore, in dogs with some degree of laryngeal paralysis,
possible upper airway obstruction and life-threatening respiratory distress [17] ought to be considered,
regardless of the anaesthetic protocol used.
In this review, most studies (83.3%) reported no statistically significant reduction in laryngeal
motion in premedicated dogs, with the majority concluding that laryngeal motion is maintained
despite the use of premedication. A low-risk-of bias, LoE II study concluded that laryngeal motion
remains above 75% despite acepromazine and methadone premedication [12]. Nevertheless, one
study found a statistically significant decrease in laryngeal function during the recovery phase in
premedicated dogs, when compared to non-premedicated dogs [6]. However, this study used the
highest dose of acepromazine (0.05 mg kg−1 IM) among all studies using later injectable induction
agent, a fact which might account for their results. In general, the effects of acepromazine on laryngeal
motion are controversial. Relatively low doses, combined with an injectional induction (alfaxalone or
propofol), resulted in absent laryngeal motion, whereas significantly higher doses of acepromazine (0.2
mg kg−1 IM), followed by inhalational anaesthesia (isoflurane), maintained laryngeal motion [6,17].
Based on these results, isoflurane mask induction might, perhaps, be considered for the evaluation of
laryngeal function. Nevertheless, a possible risk of bias must be considered, given that the study by
Tobias et al. was classified as a LoE III and was non-randomised and non-blinded [17]. Still, possible
benefits from inhalational mask induction are usually lost, due to inhalant induction being more likely
associated with complications (movement, stress and the need for restraining due to the pungent and
irritating smell, as well as potential health hazards to the personnel from repeated exposure to volatile
anaesthetics) [22–24]. Among the studies evaluating the effects of premedication on laryngeal function,
Radkey et al. contrasts positively from the others [13]. Firstly, their study design is based on an
objective assessment in a crossover design with a saline control group, which no other study included,
when analysing premedication drugs. Secondly, the examination conditions during the laryngeal
examinations were adequately reported and drug choice, as well as drug dosages and administration
rate may reflect daily clinical conditions. Their results are intriguing, since premedicated dogs had a
higher degree of laryngeal function (50%) after induction of anaesthesia than non-premedicated dogs
(0–20%), who required a significantly higher induction dose. Furthermore, after administration of
doxapram, the increase in laryngeal function was higher in premedicated dogs than non-premedicated
dogs, suggesting that the incidence of false-positive diagnosis is higher in non-premedicated dogs.
A possible explanation lies in the fact that premedicated dogs required fewer induction drugs, and
therefore, the drug-induced inhibition of the larynx may diminish, which has also been proposed by
Degroot et al. [7]. In their study, preserved laryngeal function was found in all premedicated dogs but
was absent in the same dogs anaesthetised with propofol only. This study was the only randomised
crossover study to titrate induction agents, in order to effect and adds to the evidence suggesting that
premedication preserves laryngeal function, possibly, to a better extent than using solely induction
drugs [7,12,17,18].
The majority of studies concluded no significant differences in laryngeal motion after the induction
of anaesthesia, regardless of the induction drug choice [6,10,12,14,17,18]. The same conclusion was
also reached by the two studies with the lowest risk of bias [10,12]. Nevertheless, the results are
somewhat conflicting. One study reported superior laryngeal motion with thiopental during the
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recovery phase [6]. Also, another study reported no motion in all dogs anaesthetised with alfaxalone
and 20% motion in dogs anaesthetised with propofol [13], whereas another reported less motion after
propofol, when compared to dexmedetomidine only [7].
A higher and clearer agreement seems to be found regarding the effectiveness of doxapram. The
majority of studies concluded that doxapram was useful for differentiating non-affected dogs from
dogs with laryngeal paralysis, with no serious side effects reported in healthy patients. Importantly,
doxapram administration is associated with decreases in cerebral blood flow and increases in cerebral
oxygen consumption and requirement, as well as hypertension, cardiac arrhythmias, seizures or muscle
rigidity, occurring more likely with higher dosages [25–30]. Therefore, the benefits of using doxapram
might not outweigh the risks. While all the studies administered doxapram as a bolus, constant rate
infusion (CRI) might offer the possibility to titrate doxapram to effect and may reduce the likelihood
of adverse events [31]. Given the occurrence of paradoxical motion and increased airway resistance
in dogs with laryngeal paralysis, the means for quick intubation ought to be readily available when
doxapram is administered [17,32].
A number of limitations and possible confounding factors must be considered in the present
review. Cautious interpretation of the results is warranted because of the small number of available
controlled studies and limited number of reviewed articles, with most studies, including few animals.
The introduction of a statistical type-two error is particularly high in studies which include a small
number of subjects, although most studies (58%) attempted to reduce this limitation with a crossover
design. Additionally, the study design was not ideal in most studies, with only two including a
control group [10,13] and some lacking masked observers [17,19]. Another limitation is that studies
evaluated laryngeal motion at different time points after induction of anaesthesia. Labuscagne et al.
recommended evaluating function after 2 minutes of induction because, in that time period, a higher
number of vital breaths and laryngeal movements were observed, whereas the quality of examination
was good. If the examination is either, too early or too late within the recovery phase, either absent
motions or movement artefact might be present. Another limitation is that the studies did not use a
consistent methodology, which undoubtedly can lead to assessment variations. Even with the use of
objective scoring methods, such as the calculation of the normalised glottal gap area (NGAA) from
digitised images, variations in the distance between the video scope and the glottal gap area, as well
as assessments by different evaluators, can lead to a risk of bias. Also, video laryngoscopy does not
necessarily correlate with clinical signs [2]. A potential source of error may be introduced, particularly
when the respiratory phase is not taken into account when assessing paradoxical laryngeal motion, as
paralysed arytenoid cartilages can passively move during exhalation, mimicking normal laryngeal
movements [3,33].
In comparison, direct observers have no option to pause the evaluation, which could influence
the ability to determine laryngeal function, especially during a fast breathing pattern. In general,
subjective scoring methods have the potential to introduce individual variance and inter-individual
bias when multiple evaluators performed assessments at different time points. Finally, the rate of drug
administration was inconsistent between studies. All authors administered drugs to effect, the time
period over which the drugs were administered was carried out mainly over one minute, so that the
onset of action of some drugs might have taken longer than the waited time. Also, some drugs such
as alfaxalone, induced excitement when administered slowly [13] and were therefore administered
relatively fast, which may have led to lower laryngeal motion due to higher overall administered dose.
Finally, the fact that studies analysed drugs in healthy animals is important to consider because their
side-effects can be significantly more pronounced in older animals, where laryngeal paralysis is most
frequent [3,34].
5. Conclusions
The goal of anaesthesia during the evaluation of laryngeal function in dogs should be aimed at
providing adequate sedation, while maintaining laryngeal motion and reflexes mostly intact. While
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there might not be sufficient evidence to clearly recommend one single anaesthetic regime for the
evaluation of laryngeal function in dogs, current evidence suggests that premedication maintains
overall adequate laryngeal motion in dogs and provides better conditions for laryngeal examination
than achieved with solely use of induction agents. Doxapram is effective in differentiating normal
dogs from dogs with laryngeal paralysis, but has associated safety hazards.
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